C. Zang

发表

Compound 48, a novel dual PPAR alpha/gamma ligand, inhibits the growth of human CML cell lines and enhances the anticancer-effects of imatinib.

H. Koeffler, K. Possinger, Hongyu Liu, 2009, Leukemia research.

Molecular analysis of acute intermittent porphyria: mutation screening in 20 patients in Germany reveals 11 novel mutations.

H. Schlechte, P. Petrides, T. Haverkamp, 2004, Blood cells, molecules & diseases.

Dual PPARα/γ Ligand TZD18 Either Alone or in Combination with Imatinib Inhibits Proliferation and Induces Apoptosis of Human CML Cell Lines

H. Koeffler, K. Possinger, Hongyu Liu, 2006, Cell cycle.

Targeting multiple tyrosine kinase receptors with Dovitinib blocks invasion and the interaction between tumor cells and cancer-associated fibroblasts in breast cancer

H. Riess, Hongyu Liu, P. Habbel, 2015, Cell cycle.

Induction of endoplasmic reticulum stress response by TZD18, a novel dual ligand for peroxisome proliferator-activated receptor α/γ, in human breast cancer cells

H. Koeffler, K. Possinger, Hongyu Liu, 2009, Molecular Cancer Therapeutics.

The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.

K. Possinger, A. Regierer, Hongyu Liu, 2011, Anticancer research.

Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma

O. Sezer, M. Kaiser, C. Jakob, 2006, Anti-cancer drugs.

Ligands of peroxisome proliferator-activated receptor &ggr; induce apoptosis in multiple myeloma

O. Sezer, K. Possinger, C. Jakob, 2004, Anti-cancer drugs.

Tumor Cell-selective Synergism of TRAIL- and ATRA-induced Cytotoxicity in Breast Cancer Cells.

K. Possinger, Hongyu Liu, Annekathrin Reinhardt, 2018, Anticancer research.

Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.

P. Petrides, F. Loher, C. Zang, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Autocrine regulation of matrix metalloproteinase-9 gene expression and secretion by tumor necrosis factor-α (TNF-α) in NB4 leukemic cells: specific involvement of TNF receptor type 1

F. Lottspeich, P. Petrides, C. Zang, 1998, Leukemia.

The mTOR inhibitor everolimus in combination with carboplatin in metastatic breast cancer--a phase I trial.

K. Possinger, P. Martus, A. Regierer, 2012, Anticancer research.

ADNP prompts the cisplatin-resistance of bladder cancer via TGF-β-mediated epithelial-mesenchymal transition (EMT) pathway

Xiang Hu, Shuanglin Xiang, Jian Zhang, 2021, Journal of Cancer.

The multi-tyrosine kinase inhibitor TKI258, alone or in combination with RAD001, is effective for treatment of human leukemia with BCR-ABL translocation in vitro.

Hongyu Liu, P. Habbel, C. Scholz, 2014, Anticancer research.

TKI258, a multi-tyrosine kinase inhibitor is efficacious against human infant/childhood lymphoblastic leukemia in vitro.

Hongyu Liu, P. Habbel, C. Scholz, 2014, Anticancer research.

Enhanced migration of the acute promyelocytic leukemia cell line NB4 under in vitro conditions during short-term all-trans-retinoic acid treatment

Hongyu Liu, P. Petrides, C. Zang, 2000, Journal of Cancer Research and Clinical Oncology.

Autocrine regulation of matrix metalloproteinase-9 gene expression and secretion by tumor necrosis factor-alpha (TNF-alpha) in NB4 leukemic cells: specific involvement of TNF receptor type 1.

F. Lottspeich, P. Petrides, C. Zang, 1998, Leukemia.

Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down‐regulation of Mcl‐1 in mantle cell lymphoma

B. Dörken, P. Daniel, C. Scholz, 2013, International journal of cancer.

LINC01094 Predicts Poor Prognosis in Patients With Gastric Cancer and is Correlated With EMT and Macrophage Infiltration

J. Eucker, C. Zang, Yuan-Yuan Ye, 2022, Technology in cancer research & treatment.

Novel Therapeutic Approach: Ligands for PPARγ and Retinoid Receptors Induce Apoptosis in bcl-2-positive Human Breast Cancer Cells

D. Heber, E. Williamson, H. Koeffler, 2002, Breast Cancer Research and Treatment.

A novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells.

K. Possinger, Hong-yu Liu, C. Zang, 2004, Acta pharmacologica Sinica.

Ligands for PPARγ and RAR Cause Induction of Growth Inhibition and Apoptosis in Human Glioblastomas

A. von Deimling, K. Black, C. Stadelmann, 2003, Journal of Neuro-Oncology.

Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma

M. Lenarz, K. Possinger, Hongyu Liu, 2014, Leukemia & lymphoma.

Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARα/γ ligand TZD18

H. Koeffler, K. Possinger, Hongyu Liu, 2006 .

Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18.

H. Koeffler, K. Possinger, Hongyu Liu, 2006, Blood.

Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.

K. Possinger, Hongyu Liu, C. Scholz, 2013, Cancer letters.

Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.

K. Possinger, A. Regierer, Hongyu Liu, 2012, Anticancer research.

Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.

K. Possinger, Hongyu Liu, J. Eucker, 2008, European journal of pharmacology.

Growth inhibition and apoptosis in human Philadelphia chromosome – positive lymphoblastic leukemia cell lines by treatment with the dual PPAR / ligand TZD 18

H. Koeffler, K. Possinger, Hongyu Liu, 2006 .

NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer

I. Esposito, E. Wolf, G. Schneider, 2021, bioRxiv.

Peroxisome proliferator-activated receptor gamma ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia.

K. Possinger, Hongyu Liu, H. Phillip Koeffler, 2004, Leukemia research.

Pretreatment of BMSCs with TZD solution decreases the proliferation rate of MCF-7 cells by reducing FGF4 protein expression

K. Possinger, N. Miswan, B. Khoo, 2016, Molecular medicine reports.

Somatic mutations in peroxisome proliferator-activated receptor-gamma are rare events in human cancer cells.

A. von Deimling, W. Mueller, M. Posch, 2004, Medical science monitor : international medical journal of experimental and clinical research.

Actionable loss of SLF2 drives B‐cell lymphomagenesis and impairs the DNA damage response

F. Bassermann, S. Müller, S. Kossatz, 2023, EMBO molecular medicine.

PPARγ Ligands and ATRA Inhibit the Invasion of Human Breast Cancer Cells in vitro

K. Possinger, H. Liu, M. Fenner, 2003, Breast Cancer Research and Treatment.

The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling

O. Sezer, M. Mieth, M. Kaiser, 2013, European journal of haematology.

Coincidence of Gaucher's disease due to a 1226G/1448C mutation and of an immunoglobulin G lambda multiple myeloma with Bence-Jones proteinuria

K. Possinger, E. Beutler, P. Petrides, 2000, Annals of Hematology.